Bicara Therapeutics Inc. Common Stock

10-Year Study

BCAX.US · Healthcare · US · Common Stock

Executive Summary: Bicara Therapeutics Inc. Common Stock has compounded at -3.9% annually over the last 10 years, with a maximum drawdown of 63.7% and an annualized volatility of 566.3%.

1Y CAGR
+181.9%
3Y CAGR
-3.9%
5Y CAGR
-3.9%
10Y CAGR
-3.9%

History & Riski10-year historical performance analysis including CAGR, Max Drawdown, Sharpe & Sortino ratios, annual returns, and rolling volatility — all computed from daily market data.

10-Year Growth of $10,000

Max DrawdownMax DrawdownThe largest peak-to-trough decline in the asset's value over the measurement period.Click for full definition →
63.7%
Sharpe RatioSharpe RatioRisk-adjusted return: how much excess return you earn per unit of total risk (volatility).Click for full definition →
0.17
Sortino RatioSortino RatioLike Sharpe, but only penalizes downside volatility — a more accurate risk measure for asymmetric return distributions.Click for full definition →
0.23
Ann. VolatilityAnnualized VolatilityThe annualized standard deviation of an asset's returns — a measure of how much prices fluctuate.Click for full definition →
58.5%
Best YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2026 · +42.2%
Worst YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2025 · -3.4%
% Positive Years% Positive YearsThe percentage of calendar years in the measurement period where the asset delivered a positive return.Click for full definition →
50%

Annual Returns

Rolling 12-Month Returns

Rolling 12-Month Annualised Volatility

Historical Drawdowns

Monthly Returns

Monthly Returns Heatmap

YearJanFebMarAprMayJunJulAugSepOctNovDecAnn.
2026-0.2-0.118.520.3————————42.2%
2025-27.65.4-2.010.3-35.60.419.67.532.22.914.2-9.3-3.4%
2024—————————-7.0-12.2-16.2-31.6%

Risk X-RayiA 19-factor macroeconomic risk decomposition showing exactly which market forces (equity beta, rates, inflation, credit, commodity, crypto) drive this asset's volatility. Powered by multivariate regression against daily factor returns.

Risk Profile Insight: This asset has an estimated annualized volatility of 566.3%. The dominant macroeconomic risk driver is SHV.US, accounting for 44.3% of variance. Idiosyncratic stock-specific factors contribute 0.2%.

10-Year Historical Price Series (Growth of $10,000)
DateSimulated Value
2024-09-0110000
2024-10-019297.212406753042
2024-11-018162.544169611308
2024-12-016839.418924224578
2025-01-014954.848841774637
2025-02-015221.829603455046
2025-03-015115.822536317236
2025-04-015641.931684334511
2025-05-013631.7235963879075
2025-06-013647.42834707499
2025-07-014361.99450333726
2025-08-014687.868080094228
2025-09-016199.450333725952
2025-10-016380.0549666274055
2025-11-017287.004318806439
2025-12-016607.773851590106
2026-01-016595.995288574794
2026-02-016588.142913231253
2026-03-017809.1872791519445
2026-04-019395.36709854731
Annual Return Matrix
YearAnnual Return
2025-0.03386911595866837
20260.4218657159833632
Total Factor Risk
5.662770637559205
VTI.US Exposure
0.03526375715832865
VEA.US Exposure
0.002402236997450756
VWO.US Exposure
0.03320939970676021
QQQ.US Exposure
-0.0010706807638265852
VTV.US Exposure
0.0001143638197388488
IJR.US Exposure
0.0013486310425874777
QUAL.US Exposure
0.07770414750221956
SHV.US Exposure
0.44298006568286485
TLT.US Exposure
0.09881489585797229
LQD.US Exposure
0.07470177285047468
HYG.US Exposure
0.19242600436611387
GLD.US Exposure
-0.00040931224990121057
USO.US Exposure
-0.00014484695560732682
VNQ.US Exposure
0.001210730107843361
BTC-USD.CC Exposure
-0.0007625844079215628
CPER.US Exposure
-0.000015448503883010866
VIX.INDX Exposure
0.010426453498545065
UUP.US Exposure
0.011639924670420793
TIP.US Exposure
0.018366925291328013
Idiosyncratic Exposure
0.0017935643284914707
Value Score
50
Growth Score
50
Profit Score
37.5
Health Score
23.6
Yield Score
0
Moat Score
40

Factor Risk Decomposition

Share of annualised volatility attributable to each macro factor.

Total Est. Vol
566.3%

FundamentalsiCompany financial health metrics: P/E valuation, dividend yield, Piotroski F-Score (9-point profitability signal), Altman Z-Score (bankruptcy risk proxy), and a radar chart across 6 fundamental dimensions. Note: ETFs may show N/A for some metrics.

Fundamental Dimensions

Core Valuation

P/E Ratio (TTM)P/E RatioPrice-to-Earnings ratio — the market price of a stock divided by its earnings per share, a key valuation measure.Click for full definition →N/A
Dividend YieldDividend YieldAnnual dividend paid per share divided by the current share price — expressed as a percentage income return.Click for full definition →0.00%
Market Cap$1.4B
Piotroski F-ScorePiotroski F-ScoreA 9-point scoring system evaluating a company's financial strength across profitability, leverage, and operating efficiency.Click for full definition →
9-point profitability signal
0.0/ 9
Weak
Altman Z-ScoreAltman Z-ScoreA bankruptcy prediction model that combines 5 financial ratios into a single score indicating financial distress risk.Click for full definition →
Bankruptcy risk proxy
1.18
Distress Zone
Income Simulation

Based on $10,000 initial investment.

Total Income Generated
$0
Avg Yield on Cost
0.00%

Momentum & MacroiPrice momentum indicators relative to key technical levels: distance from 50-Day SMA (intermediate trend), 200-Day SMA (long-term trend), 52-Week High (bullish proximity), and Beta (market sensitivity coefficient).

vs 50-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+30.1%
Above/below 50-day moving average
vs 200-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+54.3%
Above/below 200-day moving average
vs 52-Week High52-Week HighThe highest price an asset reached in the past 52 weeks — a key reference for momentum and valuation context.Click for full definition →
0.0% from high
Distance from 52-week high
BetaBetaA measure of an asset's sensitivity to broad market movements relative to a benchmark (e.g. S&P 500).Click for full definition →
1.00
Market sensitivity coefficient

Frequently Asked Questions & Methodology

Is Bicara Therapeutics Inc. Common Stock a high-risk investment?

Bicara Therapeutics Inc. Common Stock (BCAX.US) has an annualized volatility of 566.3% and experienced a maximum drawdown of 63.7% over the last 10 years. Its primary macro risk driver is SHV.US.

What is the 10-year return of BCAX.US?

Over the past 10 years, BCAX.US has generated a Compound Annual Growth Rate (CAGR) of -3.9%. It has had a positive return in 50% of the years measured.

Data Methodology & Trust

The risk and return information on this page is pre-calculated mathematically using daily market data spanning a 10-year period. Fundamentals (such as P/E Ratio, Market Cap, and Dividend Yield) represent trailing averages and may not immediately reflect real-time live market fluctuations. Advanced scoring models like the Piotroski F-Score and Altman Z-Score are proxies applied to publicly available trailing-twelve-month financial statements and may not account for recent off-balance-sheet events, qualitative company shifts, or sector-specific capital structures. Macroeconomic factor exposures are estimated via multivariate regression against standard market indices. This data is provided for quantitative insight and backtesting research, and should not be misconstrued as tailored financial advice.

Run a Full Backtest on Bicara Therapeutics Inc. Common Stock

stresstest.pro lets you simulate DCA vs Lump Sum, Monte Carlo projections, portfolio optimisation, and more — all in seconds.

Start a Free Backtest